An inflammatory cascade leading to hyperresistinemia in humans

PLoS Medicine

Volumn 1, Issue , 2004, Pages 161-168

  Lehrke, Michael ^a   Reilly, Muredach P ^a,b   Millington, Segan C ^a   Iqbal, Nayyar ^a   Rader, Daniel J ^a,b   Lazar, Mitchell A ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; ACETYLSALICYLIC ACID; ANTIINFLAMMATORY AGENT; BENZYLOXYCARBONYLLEUCYLLEUCYLLEUCINAL; CYTOKINE; ENDOTOXIN; I KAPPA B; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INSULIN SENSITIZING AGENT; RESISTIN; ROSIGLITAZONE; SN 50; TUMOR NECROSIS FACTOR ALPHA RECEPTOR; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; ATHEROSCLEROSIS; ATTENUATION; CELL DIFFERENTIATION; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOKINE RELEASE; DOSE RESPONSE; DRUG EFFECT; ENDOTOXEMIA; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; INFLAMMATION; INSULIN RESISTANCE; MACROPHAGE; MALE; MONOCYTE; NON INSULIN DEPENDENT DIABETES MELLITUS; NORMAL HUMAN; OBESITY; PROTEIN EXPRESSION; PROTEIN INDUCTION; IMMUNOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; REVIEW;

CELL DIFFERENTIATION; CYTOKINES; DIABETES MELLITUS, TYPE 2; ENDOTOXINS; INFLAMMATION; INSULIN RESISTANCE; MACROPHAGES; OBESITY;

EID: 15744399190     PISSN: 15491277     EISSN: None     Source Type: Journal    
DOI: 10.1371/journal.pmed.0010045     Document Type: Article

References (50)

1. Ogden CL, Carroll MD, Flegal KM (2003) Epidemiologic trends in overweight and obesity. Endocrinol Metab Clin North Am 32: 741-760.
2. Flier JS (2004) Obesity wars: Molecular progress confronts an expanding epidemic. Cell 116: 337-350.
3. Sowers JR, Frohlich ED (2004) Insulin and insulin resistance: Impact on blood pressure and cardiovascular disease. Med Clin North Am 88: 63-82.
4. Haffner SM (2003) Insulin resistance, inflammation, and the prediabetic state. Am J Cardiol 92: 18J-26J.
5. Rajala MW, Scherer PE (2003) Minireview: The adipocyte - at the crossroads of energy homeostasis, inflammation, and atherosclerosis. Endocrinology 144: 3765-3773.
6. Hotamisligil GS (2003) Inflammatory pathways and insulin action. Int J Obes Relat Metab Disord 27 (Suppl 3): S53-S55.
7. Weisberg SP, McCann D, Desai M, Rosenbaum M, Leibel RL, et al. (2003) Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest 112: 1796-1808.
8. Xu H, Barnes GT, Yang Q, Tan G, Yang D, et al. (2003) Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. J Clin Invest 112: 1821-1830.
9. Charriere G, Cousin B, Arnaud E, Andre M, Bacou F, et al. (2003) Preadipocyte conversion to macrophage. Evidence of plasticity. J Biol Chem 278: 9850-9855.
10. Glass CK, Witztum JL (2001) Atherosclerosis: The road ahead. Cell 104: 503-516.
11. Steppan CM, Bailey ST, Bhat S, Brown EJ, Banerjee RR, et al. (2001) The hormone resistin links obesity to diabetes. Nature 409: 307-312.
12. Kim KH, Lee K, Moon YS, Sul HS (2001) A cysteine-rich adipose tissue-specific secretory factor inhibits adipocyte differentiation. J Biol Chem 276: 11252-11256.
13. Rajala MW, Obici S, Scherer PE, Rossetti L (2003) Adipose-derived resistin and gut-derived resistin-like molecule-beta selectively impair insulin action on glucose production. J Clin Invest 111: 225-230.
14. Banerjee RR, Rangwala SM, Shapiro JS, Rich AS, Rhoades B, et al. (2004) Regulation of fasted blood glucose by resistin. Science 303: 1195-1198.
15. Savage DB, Sewter CP, Klenk ES, Segal DG, Vidal-Puig A, et al. (2001) Resistin/Fizz3 expression in relation to obesity and peroxisome proliferator-activated receptor-gamma action in humans. Diabetes 50: 2199-2202.
16. Patel L, Buckels AC, Kinghorn IJ, Murdock PR, Holbrook JD, et al. (2003) Resistin is expressed in human macrophages and directly regulated by PPAR gamma activators. Biochem Biophys Res Commun 300: 472-476.
17. Tan MS, Chang SY, Chang DM, Tsai JC, Lee YJ (2003) Association of resistin gene 3′-untranslated region+62GA polymorphism with type 2 diabetes and hypertension in a Chinese population. J Clin Endocrinol Metab 88: 1258-1263.
18. Smith SR, Bai F, Charbonneau C, Janderova L, Argyropoulos G (2003) A promoter genotype and oxidative stress potentially link resistin to human insulin resistance. Diabetes 52: 1611-1618.
19. Youn BS, Yu KY, Park HJ, Lee NS, Min SS, et al. (2004) Plasma resistin concentrations measured by enzyme-linked immunosorbent assay using a newly developed monoclonal antibody are elevated in individuals with type 2 diabetes mellitus. J Clin Endocrinol Metab 89: 150-156.
20. Fujinami A, Obayashi H, Ohta K, Ichimura T, Nishimura M, et al. (2004) Enzyme-linked immunosorbent assay for circulating human resistin: Resistin concentrations in normal subjects and patients with type 2 diabetes. Clin Chim Acta 339: 57-63.
21. Silha JV, Krsek M, Skrha JV, Sucharda P, Nyomba BL, et al. (2003) Plasma resistin, adiponectin and leptin levels in lean and obese subjects: Correlations with insulin resistance. Eur J Endocrinol 149: 331-335.
22. Pfutzner A, Langenfeld M, Kunt T, Lobig M, Forst T (2003) Evaluation of human resistin assays with serum from patients with type 2 diabetes and different degrees of insulin resistance. Clin Lab 49: 571-576.
23. McTernan PG, Fisher FM, Valsamakis G, Chetty R, Harte A, et al. (2003) Resistin and type 2 diabetes: Regulation of resistin expression by insulin and rosiglitazone and the effects of recombinant resistin on lipid and glucose metabolism in human differentiated adipocytes. J Clin Endocrinol Metab 88: 6098-6106.
24. Lee JH, Chan JL, Yiannakouris N, Kontogianni M, Estrada E, et al. (2003) Circulating resistin levels are not associated with obesity or insulin resistance in humans and are not regulated by fasting or leptin administration: Cross-sectional and interventional studies in normal, insulin-resistant, and diabetic subjects. J Clin Endocrinol Metab 88: 4848-4856.
25. Degawa-Yamauchi M, Bovenkerk JE, Juliar BE, Watson W, Kerr K, et al. (2003) Serum resistin (FIZZ3) protein is increased in obese humans. J Clin Endocrinol Metab 88: 5452-5455.
26. Azuma K, Katsukawa F, Oguchi S, Murata M, Yamazaki H, et al. (2003) Correlation between serum resistin level and adiposity in obese individuals. Obes Res 11: 997-1001.
27. Reilly MP, Iqbal N, Schutta M, Wolfe ML, Scally M, et al. (2004) Plasma leptin levels are associated with coronary atherosclerosis in type 2 diabetes. J Clin Endocrinol Metab 89: 3872-3878.
28. Kaser S, Kaser A, Sandhofer A, Ebenbichler CF, Tilg H, et al. (2003) Resistin messenger-RNA expression is increased by proinflammatory cytokines in vitro. Biochem Biophys Res Commun 309: 286-290.
29. Idriss HT, Naismith JH (2000) TNF alpha and the TNF receptor superfamily: Structure-function relationship(s). Microsc Res Tech 50: 184-195.
30. Van Amersfoort ES, Van Berkel TJ, Kuiper J (2003) Receptors, mediators, and mechanisms involved in bacterial sepsis and septic shock. Clin Microbiol Rev 16: 379-414.
31. Ricote M, Li AC, Willson TM, Kelly CJ, Glass CK (1998) The peroxisome proliferator-activated receptor-γ is a negative regulator of macrophage activation. Nature 391: 79-82.
32. Yuan M, Konstantopoulos N, Lee J, Hansen L, Li ZW, et al. (2001) Reversal of obesity- and diet-induced insulin resistance with salicylates or targeted disruption of Ikkbeta. Science 293: 1673-1677.
33. Palombella VJ, Rando OJ, Goldberg AL, Maniatis T (1994) The ubiquitin-proteasome pathway is required for processing the NF-kappa B1 precursor protein and the activation of NF-kappa B. Cell 78: 773-785.
34. Lin YZ, Yao SY, Veach RA, Torgerson TR, Hawiger J (1995) Inhibition of nuclear translocation of transcription factor NF-kappa B by a synthetic peptide containing a cell-permeable motif and nuclear localization sequence. J Biol Chem 270: 14255-14258.
35. Soop M, Duxbury H, Agwunobi AO, Gibson JM, Hopkins SJ, et al. (2002) Euglycemic hyperinsulinemia augments the cytokine and endocrine responses to endotoxin in humans. Am J Physiol Endocrinol Metab 282: E1276-E1285.
36. Fernandez-Real JM, Ricart W (2003) Insulin resistance and chronic cardiovascular inflammatory syndrome. Endocr Rev 24: 278-301.
37. Agwunobi AO, Reid C, Maycock P, Little RA, Carlson GL (2000) Insulin resistance and substrate utilization in human endotoxemia. J Clin Endocrinol Metab 85: 3770-3778.
38. Suffredini AF, Fromm RE, Parker MM, Brenner M, Kovacs JA, et al. (1989) The cardiovascular response of normal humans to the administration of endotoxin. N Engl J Med 321: 280-287.
39. Martich GD, Boujoukos AJ, Suffredini AF (1993) Response of man to endotoxin. Immunobiology 187: 403-416.
40. Levi M, van der Poll T, ten Cate H, van Deventer SJ (1997) The cytokine-mediated imbalance between coagulant and anticoagulant mechanisms in sepsis and endotoxaemia. Eur J Clin Invest 27: 3-9.
41. Panidis D, Koliakos G, Kourtis A, Farmakiotis D, Mouslech T, et al. (2004) Serum resistin levels in women with polycystic ovary syndrome. Fertil Steril 81: 361-366.
42. Zhang JL, Qin YW, Zheng X, Qiu JL, Zou DJ (2003) Serum resistin level in essential hypertension patients with different glucose tolerance. Diabet Med 20: 828-831.
43. Bajaj M, Suraamornkul S, Hardies LJ, Pratipanawatr T, DeFronzo RA (2004) Plasma resistin concentration, hepatic fat content, and hepatic and peripheral insulin resistance in pioglitazone-treated type II diabetic patients. Int J Obes Relat Metab Disord 28: 783-789.
44. Hotamisligil GS, Shargill NS, Spiegelman BM (1993) Adipose expression of tumor necrosis factor-α: Direct role in obesity-linked insulin resistance. Science 259: 87-91.
45. Tsigos C, Papanicolaou DA, Kyrou I, Defensor R, Mitsiadis CS, et al. (1997) Dose-dependent effects of recombinant human interleukin-6 on glucose regulation. J Clin Endocrinol Metab 82: 4167-4170.
46. Lehrke M, Lazar MA (2004) Inflamed about obesity. Nat Med 10: 126-127.
47. Takeda K, Kaisho T, Akira S (2003) Toll-like receptors. Annu Rev Immunol 21: 335-376.
48. Cohen J (2002) The immunopathogenesis of sepsis. Nature 420: 885-891.
49. Satoh H, Nguyen MT, Miles PD, Imamura T, Usui I, et al. (2004) Adenovirus-mediated chronic "hyper-resistinemia" leads to in vivo insulin resistance in normal rats. J Clin Invest 114: 224-231.
50. Rangwala SM, Rich AS, Rhoades B, Shapiro JS, Obici S, et al. (2004) Abnormal glucose homeostasis due to chronic hyperresistinemia. Diabetes53: 1937-1941.